Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Current Opinion in Drug Discovery & Development
|
August 8, 2006
Advances in cathepsin S inhibitor design
John O Link, Sheila Zipfel
Antimicrobial Agents and Chemotherapy
|
June 30, 2016
Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein
Eric J Lawitz, Hadas Dvory-Sobol, Brian P Doehle, et al.
Plos One
|
April 10, 2015
Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent
Hyock Joo Kwon, Weimei Xing, Katie Chan, et al.
Journal of Hepatology
|
February 9, 2012
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
Eric J Lawitz, Daniel Gruener, John M Hill, et al.
Antimicrobial Agents and Chemotherapy
|
January 30, 2016
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir
Guofeng Cheng, Yang Tian, Brian Doehle, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 8, 2024
Lenacapavir Exhibits Atropisomerism-Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway
Jim Zheng, Bing Lu, Gavin Carr, et al.
Journal of Medicinal Chemistry
|
December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection
John O Link, James G Taylor, Lianhong Xu, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 25, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi<sup>®</sup> and Epclusa<sup>®</sup>
John O Link, James G Taylor, Alejandra Trejo-Martin, et al.
ACS Medicinal Chemistry Letters
|
April 17, 2024
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873
Darryl Kato, Regina Wai-Yan Choy, Eda Canales, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 29, 2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi<sup>®</sup>
James G Taylor, Sheila Zipfel, Kyla Ramey, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Current Opinion in Drug Discovery & Development
|
August 8, 2006
Advances in cathepsin S inhibitor design
John O Link, Sheila Zipfel
Antimicrobial Agents and Chemotherapy
|
June 30, 2016
Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein
Eric J Lawitz, Hadas Dvory-Sobol, Brian P Doehle, et al.
Plos One
|
April 10, 2015
Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent
Hyock Joo Kwon, Weimei Xing, Katie Chan, et al.
Journal of Hepatology
|
February 9, 2012
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
Eric J Lawitz, Daniel Gruener, John M Hill, et al.
Antimicrobial Agents and Chemotherapy
|
January 30, 2016
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir
Guofeng Cheng, Yang Tian, Brian Doehle, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 8, 2024
Lenacapavir Exhibits Atropisomerism-Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway
Jim Zheng, Bing Lu, Gavin Carr, et al.
Journal of Medicinal Chemistry
|
December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection
John O Link, James G Taylor, Lianhong Xu, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 25, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi<sup>®</sup> and Epclusa<sup>®</sup>
John O Link, James G Taylor, Alejandra Trejo-Martin, et al.
ACS Medicinal Chemistry Letters
|
April 17, 2024
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873
Darryl Kato, Regina Wai-Yan Choy, Eda Canales, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 29, 2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi<sup>®</sup>
James G Taylor, Sheila Zipfel, Kyla Ramey, et al.
Page
of 2